Cubist’s Sivextro To Beat Durata’s Dalvance To Antibiotic Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Second QIDP antibiotic is first to market; Cubist will stress shorter term dosing over available therapies and thinks it can rely on efficient marketing strategy for commercial success.